Marumo Takeshi, Yagi Shintaro, Kawarazaki Wakako, Nishimoto Mitsuhiro, Ayuzawa Nobuhiro, Watanabe Atsushi, Ueda Kohei, Hirahashi Junichi, Hishikawa Keiichi, Sakurai Hiroyuki, Shiota Kunio, Fujita Toshiro
Division of Clinical Epigenetics, Research Center for Advanced Science and Technology, CREST, Japan Science and Technology Agency, Tokyo, Japan;
Laboratory of Cellular Biochemistry, Department of Animal Resource Sciences/Veterinary Medical Sciences, and.
J Am Soc Nephrol. 2015 Oct;26(10):2388-97. doi: 10.1681/ASN.2014070665. Epub 2015 Feb 4.
Epigenetic mechanisms may underlie the progression of diabetic kidney disease. Because the kidney is a heterogeneous organ with different cell types, we investigated DNA methylation status of the kidney in a cell type-specific manner. We first identified genes specifically demethylated in the normal proximal tubules obtained from control db/m mice, and next delineated the candidate disease-modifying genes bearing aberrant DNA methylation induced by diabetes using db/db mice. Genes involved in glucose metabolism, including Sglt2, Pck1, and G6pc, were selectively hypomethylated in the proximal tubules in control mice. Hnf4a, a transcription factor regulating transporters for reabsorption, was also selectively demethylated. In diabetic mice, aberrant hypomethylation of Agt, Abcc4, Cyp4a10, Glut5, and Met and hypermethylation of Kif20b, Cldn18, and Slco1a1 were observed. Time-dependent demethylation of Agt, a marker of diabetic kidney disease, was accompanied by histone modification changes. Furthermore, inhibition of DNA methyltransferase or histone deacetylase increased Agt mRNA in cultured human proximal tubular cells. Aberrant DNA methylation and concomitant changes in histone modifications and mRNA expression in the diabetic kidney were resistant to antidiabetic treatment with pioglitazone. These results suggest that an epigenetic switch involving aberrant DNA methylation causes persistent mRNA expression of select genes that may lead to phenotype changes of the proximal tubules in diabetic kidney disease.
表观遗传机制可能是糖尿病肾病进展的基础。由于肾脏是一个由不同细胞类型组成的异质性器官,我们以细胞类型特异性的方式研究了肾脏的DNA甲基化状态。我们首先鉴定了从对照db/m小鼠获得的正常近端小管中特异性去甲基化的基因,接着使用db/db小鼠描绘了由糖尿病诱导的具有异常DNA甲基化的候选疾病修饰基因。参与葡萄糖代谢的基因,包括Sglt2、Pck1和G6pc,在对照小鼠的近端小管中选择性地低甲基化。Hnf4a,一种调节重吸收转运蛋白的转录因子,也被选择性地去甲基化。在糖尿病小鼠中,观察到Agt、Abcc4、Cyp4a10、Glut5和Met的异常低甲基化以及Kif20b、Cldn18和Slco1a1的高甲基化。糖尿病肾病标志物Agt的时间依赖性去甲基化伴随着组蛋白修饰的变化。此外,DNA甲基转移酶或组蛋白脱乙酰酶的抑制增加了培养的人近端肾小管细胞中Agt的mRNA水平。糖尿病肾脏中异常的DNA甲基化以及伴随的组蛋白修饰和mRNA表达变化对吡格列酮的抗糖尿病治疗具有抗性。这些结果表明,涉及异常DNA甲基化的表观遗传开关导致特定基因的持续mRNA表达,这可能导致糖尿病肾病中近端小管的表型变化。